• Immunocore outlined growth trajectory for KIMMTRAK in first-line metastatic uveal melanoma, reporting Q1 2026 net sales of $107 million, up 14% year over year.
• Presentation positioned KIMMTRAK as global standard of care in that setting, citing 16 consecutive quarters of growth, at least 70% penetration in major launched markets.
• Updated long-term survival data highlighted a 16% 5-year overall survival rate for tebentafusp versus 8% for investigator’s choice, with median overall survival of 21.6 months versus 16.9 months.
• Pipeline focus included Phase 3 TEBE-AM in second-line or later advanced cutaneous melanoma, with enrollment completion expected in 1H 2026, primary endpoint overall survival.
• Company also highlighted Phase 3 PRISM-MEL-301 for brenetafusp in first-line advanced cutaneous melanoma, alongside earlier-stage programs spanning solid tumors, HIV, type 1 diabetes, atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.